Precision Guided Tacrolimus Dosing in Pediatric Heart Transplant

단계 해당 없음 완료 NCT04380311

요약

Immunosuppressive therapy is required to prevent organ rejection, however, dosing of immunosuppressive agents is complicated by patient-specific differences impacting the body's absorption and elimination of these agents. The goal of this research proposal is to clinically validate an innovative precision medicine strategy for dosing the immunosuppressant tacrolimus in pediatric heart transplant, which will in turn lead to improvements in long-term transplant survival outcomes. The strategy and techniques used in this project can be extended to improve drug therapy across multiple pediatric diseases requiring chronic therapy.

Time to Target Concentration Attainment

Within 6 weeks following transplant · days

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

• Implantation of a Permanent Interatrial Shunt to Reduce Left Atrial Filling Pressures Foll — samir kapadia
• Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure — Yale University
• Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
• PROACTIVE-HF IDE Trial Heart Failure NYHA Class III — Endotronix, Inc.
• Improving How Older Adults at Risk for Cardiovascular Outcomes Are Selected for Care Coord — Weill Medical College of Cornell University
• Crome/Cobalt Respiration Study — Medtronic Cardiac Rhythm and Heart Failure

전체 임상